- Lead Programs CD44 and Trop-2 poster Presentations
Reveal New Findings -
TORONTO, April 4 - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new information on the preclinical activity of two of its novel monoclonal antibodies will be presented at the Annual Meeting of the American Association for Cancer Research (AACR), which runs from April 14-18, 2007 in Los Angeles, California. The first poster presentation will outline the activity of ARIUS' lead anti-CD44 antibody, ARH460-16-2, against liver cancer, a significant market in Asia and a growing concern in North America.
CD44 is an important marker for cancer stem cells that often survive treatment and keep growing to spread tumors. Studies of patients with different types of cancer have shown that CD44 can be linked to poorer chances of survival. ARIUS anti-CD44 antibodies have previously been found to control tumor growth and improve survival in breast and prostate cancer models.
The second poster will describe the activity of two antibodies targeting Trop-2 in a variety of solid tumors including breast and colon cancers plus pancreatic cancer, an area without effective treatment options. Trop-2 is a new target for drugs in cancer. Recently, increasing Trop-2 has been shown to
stimulate tumor growth. Studies in colon cancer patients found it is also associated with more aggressive disease and cancer death.
"Presenting our most recent findings for two of our lead programs, CD44 and Trop-2, is an excellent opportunity to showcase the potential of our products as we look for partners," said Dr. David Young, President and CEO. "Moreover, this important preclinical work also highlights the value and capabilities of our FunctionFIRST(TM) platform to generate novel antibodies with promising anti-cancer properties."
Novel antibody ARH460-16-2 rec ognizes an epitope of CD44 that is highly expressed in liver cancers. Abstract 662, Section 27, Board 15, Sunday, Apr 15, 8AM - 12PM
ARH460-16-2, a functional antibody that targets CD44, has previously been shown to have anti-tumor and survival benefits in animal models of breast and prostate cancers. New immunohistochemistry (IHC) studies demonstrated high levels of ARH460-16-2 binding to primary liver tumors: 43% (21/49). The antibody also bound more frequently to metastatic than to primary hepatocellular carcinomas, 88% (7/8) versus 30% (11/37), and there was a trend towards higher binding in advanced AJCC stages in comparison with earlier stages: 0% (stage I), 12% (stage II), 50% (stage III) and 75% (stage IV). In vivo studies are currently under way, to assess the therapeutic effect of this antibody in an in vivo model of metastatic hepatocellular carcinoma.
Functional antibodies targeting Trop-2 demonstrate in vivo efficacy in human pancreatic and other solid tumor xenograft models. Abstract 904, Section 5, Board 3, Sunday, Apr 15, 1PM - 5PM
Two monoclonal antibodies directed against Trop-2, AR47A6.4.2 and AR52A301.5, have been independently generated which, in in vitro assays, induce cytotoxicity in pancreatic, colon, lung and ovarian cancer cell lines.
Experiments conducted using the human pancreatic BxPC-3 xenograft model demonstrated that treatment with these antibodies resulted in tumor growth inhibition in both prophylactic and established models. The in vivo anti-tumor efficacy of these antibodies was examined in models of other solid tumor cancer indications, and the anti-tumor effect in human pancreatic cancer was substantiated by a second model of human pancreatic cancer. With the aim of bringing these antibodies to the clinic, the selection of an animal model for toxicology studies was undertaken. Results from these studies have
demonstrated a very similar expression pattern between hum ans and cynomolgus monkeys, thereby providing a relevant candidate model for pre-clinical toxicology.
The Annual meeting of the American Association for Cancer Research (AACR) will be held at the Los Angeles Convention Center in Los Angeles, California and runs from April 14-18, 2007. Additional information about the AACR and detailed abstracts of ARIUS' poster presentations can be found at
ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARUIS is listed on the TSX under the symbol "ARI". For further information, visit www.ariusresearch.com
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or impl ied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement.
For further information: Helen Findlay, Executive Vice-President, (416)
862-2323 ext. 223, email@example.com; James Smith, Investor Relations,
(416) 815-0700 ext. 229, firstname.lastname@example.org